Thornburg Investment Management Inc. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 40.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 259,857 shares of the medical device company’s stock after purchasing an additional 74,413 shares during the quarter. Thornburg Investment Management Inc. owned approximately 0.30% of DexCom worth $12,714,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. FMR LLC grew its stake in DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after acquiring an additional 978,898 shares during the period. Janus Henderson Group PLC boosted its stake in DexCom by 101,699.8% during the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after purchasing an additional 6,822,023 shares during the last quarter. Vanguard Group Inc. boosted its stake in DexCom by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after purchasing an additional 224,808 shares during the last quarter. BlackRock Inc. boosted its stake in DexCom by 5.5% during the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after purchasing an additional 230,542 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in DexCom by 18.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock worth $288,669,000 after purchasing an additional 607,972 shares during the last quarter.

Several equities research analysts have issued reports on DXCM shares. Barclays reaffirmed an “equal weight” rating and set a $60.00 target price (down previously from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 28th. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Leerink Swann reaffirmed a “buy” rating and set a $57.00 target price (down previously from $85.00) on shares of DexCom in a research note on Friday, September 29th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $78.00 target price (down previously from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the stock. DexCom currently has an average rating of “Buy” and an average target price of $70.69.

Shares of DexCom, Inc. (DXCM) opened at $58.43 on Friday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80.

In related news, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $72.27, for a total transaction of $234,443.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,500 shares of the stock in a transaction on Monday, November 27th. The shares were sold at an average price of $54.95, for a total value of $137,375.00. Following the sale, the director now directly owns 4,952 shares in the company, valued at approximately $272,112.40. The disclosure for this sale can be found here. Insiders have sold 37,954 shares of company stock worth $2,266,296 over the last quarter. Insiders own 1.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Thornburg Investment Management Inc. Purchases 74,413 Shares of DexCom, Inc. (DXCM)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/01/thornburg-investment-management-inc-purchases-74413-shares-of-dexcom-inc-dxcm.html.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.